Q-omics provides the consensus-scored TRIM22 profile across patient tissues and cancer cell-line models. TRIM22 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, TRIM22 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, TRIM22 RNA expression shows 18,207 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SKCM, KIRC, and UVM as cancer lineages where TRIM22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM22 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM22 survival associations across molecular data types. TRIM22 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM22 RNA expression–survival associations across cancer types. High TRIM22 expression shows unfavorable associations in LUSC and LGG, but favorable associations in SKCM, KIRC, CESC and UCS. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for TRIM22 RNA expression.
This table summarizes TRIM22 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TRIM22. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM22 shows lower tumor expression in LUAD, LUSC and KICH and higher tumor expression in KIRC, THCA and KIRP. The KIRC box plot shows higher TRIM22 RNA expression in tumor versus normal tissue (log2 FC = +1.445, t-test p < 0.001).
This table shows molecular features associated with TRIM22 in patient tissues and cancer cell lines. In patient samples, TRIM22 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TRIM22 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
